---
title: "Is there a loading protocol for iron supplementation?"
url: https://nutritailor.co.uk/apps/learn/is-there-a-loading-protocol-for-iron-supplementation
slug: is-there-a-loading-protocol-for-iron-supplementation
pillar: Iron
last_reviewed: 13 May 2026
confidence: strong
publisher: "Nutri Tailor Health Reference Library"
editor: "Henry Bond"
---

# Is there a loading protocol for iron supplementation?

## Summary

No oral loading-dose protocol in current major guidelines. BSG 2021 (Snook Gut 70(11):2030-2051) recommends one tablet daily of ferrous sulphate, fumarate, or gluconate, no loading phase. Pharmacological basis: oral iron triggers hepcidin elevation blocking absorption from subsequent doses for 24-48 hours (Moretti 2015 Blood; Stoffel 2017 and 2020 Lancet Haematol). Strongest absorption strategy is alternate-day dosing. For genuine rapid repletion: IV iron (ferric carboxymaltose, ferric derisomaltose); not for self-administration.

## How it works

Stoffel 2017 (Lancet Haematology 4(11):e524-e533) confirmed the rebound in iron-depleted women using two open-label RCTs. Stoffel 2020 (Haematologica 105(5):1232-1239) extended the finding to iron-deficient anaemic women (the clinical repletion population). Li 2020 (JAMA Network Open 3(11):e2023644) individual-participant meta-analysis confirmed across studies that alternate-day dosing produces greater fractional absorption than consecutive-day dosing. The hepcidin rebound was demonstrated primarily in women; the underlying physiology applies broadly across populations.

## Effective dose

Doses above 200 mg elemental iron in a single sitting do not increase fractional absorption proportionally due to hepcidin saturation. Historical twice-daily and three-times-daily iron dosing patterns prevalent in older clinical practice have been superseded by once-daily and alternate-day approaches. IV iron formulations can deliver 1000-2000 mg elemental iron in one or two infusions; this is the appropriate loading approach when indicated.

## Forms compared

IV iron is administered in a clinical setting with monitoring for the rare but recognised risk of hypersensitivity reactions. IV iron is not appropriate for self-administration. The choice between continued oral iron and switching to IV iron is made with a healthcare provider based on the underlying cause of deficiency, the rate of correction needed, and the individual response to oral iron.

## Timing

BSG 2021 monitoring: assess haemoglobin response at 4 weeks; continue intervention for approximately 3 months after Hb normalisation to allow adequate repletion of marrow stores. Iron studies are then repeated to confirm adequate stores. The guideline does not specify a single ferritin target; response is gauged by haemoglobin recovery and resolution of iron deficiency on iron studies. Specific ferritin target numbers (e.g. 70-100 mcg/L in older nutrition literature) are not part of BSG 2021 standard practice.

## Safety profile

Iron overload risk in genetic haemochromatosis (HFE gene mutations): unsupervised high-dose iron supplementation contraindicated; ferritin monitoring before sustained supplementation reasonable in those with family history. Accidental paediatric iron overdose is a serious risk; keep supplements out of reach of children. Long-term supplementation without confirmed deficiency is not appropriate. Active inflammation may elevate ferritin into the normal range despite functional iron deficiency; transferrin saturation and CRP context required for interpretation.

## Special populations

Coeliac disease: malabsorption may make oral iron repletion slower; IV iron consideration where oral fails. Post-bariatric surgery (Roux-en-Y, sleeve gastrectomy): iron malabsorption common; oral repletion often inadequate. Heavy menstrual bleeding with severe deficiency: ongoing blood loss may exceed oral repletion capacity; IV iron and gynaecological assessment in parallel. Pre-surgery patients with iron deficiency anaemia: rapid optimisation with IV iron is increasingly standard practice in UK enhanced recovery pathways. Restless legs syndrome (RLS) with low ferritin: AASM 2024 (Winkelman J Clin Sleep Med 21(1):137-152) STRONG recommendation for IV ferric carboxymaltose at ferritin 75-100 mcg/L.

## Interactions

Calcium at supplemental doses (165 mg or above per meal): reduces non-heme and heme iron absorption (Hallberg 1991). Polyphenols (tea, coffee, red wine): form insoluble complexes with non-heme iron. Phytates (whole grains, legumes, nuts): bind non-heme iron. Zinc and iron: interact at supplemental doses in fasting conditions; inhibition largely disappears with food. Vitamin C co-administration: 2-3x absorption-level effect in single-meal isotope studies; clinical-outcome benefit (haemoglobin or ferritin response) less reliable; BSG 2021 does not specifically endorse as routine.

## Guideline positions

BSG 2021 IV iron indications: parenteral iron when oral iron is contraindicated, ineffective, or not tolerated, and at an early stage if oral iron is judged unlikely to be effective. The American Gastroenterology Association similarly recommends single-tablet daily dosing as standard. The 2018 IRLSSG iron task force consensus and 2024 AASM RLS guideline both endorse standard ferrous sulphate dosing for oral iron without loading. Tolkien 2015 (PLoS One 10(2):e0117383) for the GI side-effect profile of ferrous sulphate.

## Practical framework

IV iron is not appropriate for self-administration; it requires clinical assessment of indications and contraindications and infusion in a monitored setting. The choice between continued oral iron and switching to IV iron is made with a healthcare provider based on underlying cause, rate of correction needed, and individual response. The strongest evidence-supported absorption strategy for oral iron is alternate-day dosing , paradoxically less frequent rather than more frequent. This is a summary of published research, not personal health advice. Discuss any health or supplement decisions with a qualified healthcare professional, particularly during ongoing care, pregnancy, or with chronic conditions.

## Common misconceptions

**Claim: twice-daily or three-times-daily iron dosing accelerates repletion.** These historical patterns have been superseded by once-daily and alternate-day approaches; consecutive-day dosing produces hepcidin-mediated absorption suppression.

**Claim: ferritin target 70-100 mcg/L is the BSG endpoint.** BSG 2021 does not specify a single ferritin target; response is gauged by haemoglobin recovery and resolution of iron deficiency on iron studies.

**Claim: vitamin C co-administration is required for repletion.** BSG 2021 does not specifically endorse co-administration; absorption-level effect is real but clinical-outcome benefit less reliable.

**Claim: IV iron is appropriate self-administration for rapid repletion.** IV iron is administered only in clinical settings with monitoring; not for self-administration.

## Who this matters for

- Pregnancy
- Breastfeeding
- Adults over 65
- Vegetarian diet
- Vegan diet
- Endurance athletes
- Inflammatory bowel disease
- Kidney impairment
- People taking levothyroxine
- People taking proton pump inhibitors

## Sources

1. Snook J, Bhala N, Beales ILP, Cannings D, Kightley C, Logan RPH, Pritchard DM, Sidhu R, Surgenor S, Thomas W, Verma AM (2021). British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults. Gut. PMID: 34497146. DOI: 10.1136/gutjnl-2021-325210.
2. Moretti D, Goede JS, Zeder C, Jiskra M, Chatzinakou V, Tjalsma H, Melse-Boonstra A, Brittenham G, Swinkels DW, Zimmermann MB (2015). Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood. PMID: 26289639. DOI: 10.1182/blood-2015-05-642223.
3. Stoffel NU, Cercamondi CI, Brittenham G, Zeder C, Geurts-Moespot AJ, Swinkels DW, Moretti D, Zimmermann MB (2017). Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematology. PMID: 29032957. DOI: 10.1016/s2352-3026(17)30182-5.
4. Stoffel NU, Zeder C, Brittenham GM, Moretti D, Zimmermann MB (2020). Iron absorption from supplements is greater with alternate day than with consecutive day dosing in iron-deficient anemic women. Haematologica. PMID: 31413088. DOI: 10.3324/haematol.2019.220830.
5. Tolkien Z, Stecher L, Mander AP, Pereira DI, Powell JJ (2015). Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One. PMID: 25700159. DOI: 10.1371/journal.pone.0117383.
6. Winkelman JW, Berkowski JA, DelRosso LM, Koo BB, Scharf MT, Sharon D, Zak RS, Kazmi U, Falck-Ytter Y, Shelgikar AV, Trotti LM, Walters AS (2025). Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine. PMID: 39324694. DOI: 10.5664/jcsm.11390.
7. Allen RP, Picchietti DL, Auerbach M, Cho YW, Connor JR, Earley CJ, Garcia-Borreguero D, Kotagal S, Manconi M, Ondo W, Ulfberg J, Winkelman JW (2018). Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. Sleep Medicine. PMID: 29425576. DOI: 10.1016/j.sleep.2017.11.1126.